(Q38730609)

5 September 2017

title

Immunogenicity of Therapeutic Protein Aggregates (English)

1 reference

5 September 2017

4

Janice S Blum

1 reference

5 September 2017

Ehab M Moussa

1

1 reference

5 September 2017

Jainik P Panchal

2

1 reference

5 September 2017

Balakrishnan S Moorthy

3

1 reference

5 September 2017

Marisa K Joubert

5

1 reference

5 September 2017

Linda O Narhi

6

1 reference

5 September 2017

Elizabeth M Topp

7

1 reference

5 September 2017

language of work or name

English

0 references

publication date

1 February 2016

1 reference

Journal of Pharmaceutical Sciences

5 September 2017

published in

1 reference

5 September 2017

volume

105

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

417-430

1 reference

Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Non-native protein aggregation kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Protein aggregation: pathways, induction factors and analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Effects of protein aggregates: an immunologic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Immunogenicity of therapeutic proteins: influence of aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Forced degradation of therapeutic proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

A critical review of analytical methods for subvisible and visible particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

A critical review of methods for size characterization of non-particulate protein aggregates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Protein particles: what we know and what we do not know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Particles in therapeutic protein formulations, Part 1: overview of analytical methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

The biochemistry and cell biology of antigen processing and presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

How B cells capture, process and present antigens: a crucial role for cell polarity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Molecular determinants of immunogenicity: the immunon model of immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

The influence of antigen organization on B cell responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Role of repetitive antigen patterns for induction of antibodies against antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Antibody response against Betaferon® in immune tolerant mice: involvement of marginal zone B-cells and CD4+ T-cells and apparent lack of immunological memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Development of ADA against recombinant human interferon beta in immune tolerant mice requires rapid recruitment of CD4⁺ T cells, induces formation of germinal centers but lacks susceptibility for (most) adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

UV photodegradation of murine growth hormone: chemical analysis and immunogenicity consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

The immunogenicity of antibody aggregates in a novel transgenic mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Antibody responses in mice to particles formed from adsorption of a murine monoclonal antibody onto glass microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Dose levels in particulate-containing formulations impact anti-drug antibody responses to murine monoclonal antibody in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Antibody production to aggregated human gamma-G-globulin in acquired hypogammaglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Intravenous administration of human gamma-globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Role of aggregated human growth hormone (hGH) in development of antibodies to hGH

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Factor VIII immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Intravenous immune globulin in autoimmune and inflammatory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Immunologic responses of graft recipients to antilymphocyte globulin: effect of prior treatment with aggregate-free gamma globulin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Restoration of growth by human growth hormone (Roos) in hypopituitary dwarfs immunized by other human growth hormone preparations: clinical and immunological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Recombinant EPO production--points the nephrologist should know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Intravenous immunoglobulin: adverse effects and safe administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Classification and characterization of therapeutic antibody aggregates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of Aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Immunogenicity of aggregates of recombinant human growth hormone in mouse models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

SENSITIZATION TO DENATURED AUTOLOGOUS GAMMA GLOBULIN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

The role of soluble aggregates in the primary immune response of mice to human gamma globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Chemical modifications in therapeutic protein aggregates generated under different stress conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

T-cell-dependent antibody responses in the rat: forms and sources of keyhole limpet hemocyanin matter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Development of a transgenic mouse model immune tolerant for human interferon Beta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

How we treat a hemophilia A patient with a factor VIII inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Degradation of soluble immunoglobulin aggregates in vitro by monocytes from normal subjects and from patients with systemic lupus erythematosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Computational methods to predict therapeutic protein aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Predictive tools for stabilization of therapeutic proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

The Zyggregator method for predicting protein aggregation propensities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

The PASTA server for protein aggregation prediction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

PASTA 2.0: an improved server for protein aggregation prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Industry perspective on the medical risk of visible particles in injectable drug products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.002

10.1016/J.XPHS.2015.11.002

7 January 2021

Identifiers

DOI

1 reference

5 September 2017

1 reference